1. QIAGEN announces Q2 2025 results release on August 5. 2. Conference call scheduled for August 6 to discuss results. 3. QIAGEN is a leader in molecular insights solutions. 4. They provide technologies for biological sample analysis and automation. 5. Over 500,000 customers served globally in Life Sciences.
Consistent revenue growth expected with anticipated positive Q2 results. Positive earnings reports typically drive stock prices up historically.
Earnings announcements directly impact investor perceptions and short-term stock performance, making this news particularly significant.
Upcoming results can affect shares quickly, as seen in past quarterly reports influencing stock reactions. Market sentiment can be influenced immediately following earnings calls.
VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) today announced plans to release results for the second quarter of 2025.
Press release date / time: Tuesday, August 5, shortly after 22:05 Frankfurt time / 21:05 London time / 16:05 New York time.
Conference call date / time: Wednesday, August 6, at 15:30 Frankfurt time / 14:30 London time / 09:30 New York time.
Three options for joining the conference call
Register for call back connection - Click here: Connect me
Service is available 15 minutes before the call starts
Dial-in by phone
U.S.: +1 929 477 0402
UK: +44 (0)330 165 3655
GER: +49 (0)69 6610 2480
Conference ID: 1992038
To avoid waiting time, please join the event conference 5-10 minutes prior to the start time.
Access the audio webcast - Click here: Access Webcast
A conference call replay will be available by using the following link:
https://event.webcasts.com/viewer/event.jsp?ei=1709551&tp_key=978ad5a0e6
Contact: IR@qiagen.com
About QIAGEN
QIAGEN N.V., a Netherlands-based holding company, is the leading global provider of Sample to Insight solutions, enabling customers to extract and gain valuable molecular insights from samples containing the building blocks of life. Our sample technologies isolate and process DNA, RNA and proteins from blood, tissue and other materials. Assay technologies prepare these biomolecules for analysis while bioinformatics software and knowledge bases can be used to interpret data to find actionable insights. Automation solutions bring these processes together into seamless and cost-effective workflows. QIAGEN serves over 500,000 customers globally in Life Sciences (academia, pharma R&D and industrial applications, primarily forensics) and Molecular Diagnostics for clinical healthcare. As of March 31, 2025, QIAGEN employed more than 5,600 people in over 35 locations worldwide. For more information, visit www.qiagen.com.
category: Financial